Freenome, Inc. FRNM
9.73 USD -0.09 (-0.92%)
Regular-session close
9.87 +0.14 +1.44%
After hours · Nov 18, 6:32 PM ET
9.60 Day range 10.35
9.60 52-week range 17.50
- YTD
- -25.33%
- 1 year
- -9.49%
News
globenewswire.com Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and…
defenseworld.net Freenome (NASDAQ:FRNM) Stock Has Average Target Price of $18.00 According to Analysts Shares of Freenome (NASDAQ: FRNM - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One…
marketbeat.com Freenome Q3 Earnings Call Highlights Freenome NASDAQ: FRNM reported third-quarter revenue of $183.5 million, driven largely by revenue recognition following the U.S. Food and Drug Administration's approval of its blood-based colorectal…
benzinga.com Freenome Q3 2026 Earnings Call Transcript Freenome (NASDAQ:FRNM) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com UPDATE: Freenome Q3 Adj. EPS $1.10 Beats $0.41 Estimate, Sales $183.489M Beat $105.866M Estimate Freenome (NASDAQ:FRNM) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $0.41 by 168.29 percent. This is a 222.22 percent increase over losses of $(0.90)…
globenewswire.com Freenome Reports Third Quarter 2026 Financial Results – Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –
fool.com Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought Ark Invest added to three existing positions on Monday, all of them down sharply from recent highs.benzinga.com Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests – Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at…
globenewswire.com Freenome Expands Personalized Cancer Detection Portfolio, Launching SimpleScreen™ Lung Test With FDA-Approved SimpleScreen CRC Option – Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at…
globenewswire.com Freenome to Report Third Quarter 2026 Financial Results on November 10, 2026 BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to…
globenewswire.com Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential colorectal cancer prevention - - Overall detection of…
seekingalpha.com Freenome: SimpleScreen CRC Unlocks A 50M Patient TAM, Bypassing Competition Freenome is rated Buy, leveraging FDA-approved SimpleScreen CRC and a $410M cash reserve to target the vast unscreened colorectal market. FRNM's SimpleScreen CRC, now out-licensed to Abbott, offers a…
globenewswire.com FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen™ Lung Cancer Screening Test BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and…
reuters.com FDA approves Freenome's blood test for colorectal cancer screening The U.S. FDA has approved Freenome's blood-based colorectal cancer screening test for older adults, paving the way for partner Abbott to launch it in the U.S. this fall, the companies said on…
globenewswire.com FDA Approves Freenome's SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S. – Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader…
globenewswire.com Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection – Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 – – Gross proceeds to Freenome totaled more than $300 million through a…
